Company intelligence / Profile preview

Global Immune Technologies

Frederick, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Global Immune Technologies is a biotechnology company specializing in personalized cancer immunotherapy. The company's primary focus is the development of OncoVAX, an autologous tumor cell vaccine intended to prevent the recurrence of Stage II colon cancer following surgery. The technology involves using a patient's own tumor cells, which are processed and combined with an adjuvant to trigger a specific immune response against remaining cancer cells. Global Immune Technologies was acquired by Vaccinogen, which took over the clinical advancement of its pipeline.

Therapeutic areas: Oncology
Modalities: VaccineCell therapy
Industry: Biotech

Beyond the preview

Go deeper on Global Immune Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Global Immune Technologies.

Explore the full profile